Anebulo Pharmaceuticals Reports Q2 Fiscal 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Source: seekingalpha
- Financial Overview: Anebulo Pharmaceuticals reported a GAAP EPS of -$0.05 for Q2 of fiscal 2026, indicating ongoing challenges in profitability that may affect investor confidence.
- Stable Operating Expenses: Total operating expenses for the second quarter were $2.6 million, unchanged from the same period in fiscal 2025, suggesting the company has maintained cost control despite a lack of significant revenue growth.
- Cash Position: As of December 31, 2025, the company had $9.0 million in cash and cash equivalents, reflecting a reasonable liquidity position, but future funding needs remain a concern.
- Loan Agreement Support: The company has access to an additional $3.0 million in cash through a loan agreement, providing financial support for future operations and R&D, which may help accelerate product development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
